Clinical Trial Update: Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

The entry details the completion of a Phase 1 trial evaluating Bryostatin 1 in combination with Interleukin-2 in patients with refractory solid tumors and lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Institute on Aging (NIA) | Conditions: Lymphoma, Small Intestine Cancer | Phase 1 | Status: COMPLETED